G5547

GSK837149A

≥98% (HPLC), solid

• Sinónimos: N,N′-Di[4-(4-Methyl-pyrimidin-2-ylsulfamoyl)phenyl]-urea
• Fórmula empírica (notación de Hill): C₂₃H₂₂N₈O₅S₂
• Número CAS: 13616-29-0
• Peso molecular: 554.60
• MDL number: MFCD00133992
• NACRES: NA.77
• UNSPSC Code: 51111800
• Assay: ≥98% (HPLC)
• Form: solid

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• color: white to off-white
• solubility: DMSO: >10 mg/mL, H₂O: insoluble
• originator: GlaxoSmithKline
• storage temp.: 2-8°C

Descripción

Biochem/physiol Actions

GSK837149A is a selective inhibitor of human fatty acid synthase (FAS).

GSK837149A is the first selective inhibitor of human fatty acid synthase (FAS) known to act specifically and selectively on the KR activity of the enzyme. It was first isolated as a minor impurity in a sample found to be active against the enzyme in a high-throughput screening campaign. This compound and its analogs synthesized, all being symmetrical structures containing a bisulfonamide urea, act by inhibiting the beta-ketoacyl reductase activity of the enzyme. GSK837149A inhibits FAS in a reversible mode, with a Ki value of approximately 30 nm, and it possibly binds to the enzyme-ketoacyl-ACP complex. Although initial results suggest that cell penetration for these compounds is impaired, they still can be regarded as useful tools with which to probe and explore the beta-ketoacyl reductase active site in FAS, helping in the design of new inhibitors.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H319
• pcodes: P264 - P280 - P305 + P351 + P338 - P337 + P313
• Hazard Classifications: Eye Irrit. 2
• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: dust mask type N95 (US), Eyeshields, Gloves